All In Biotech

Drug Trial Radar · NCT06467357

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 620 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

620

Planned (sponsor's estimate)

Start

Aug 12, 2024

Primary completion

Jun 12, 2028

Study completion May 16, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jun 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naïve HER2-expressing BTC.

Conditions

  • Biliary Tract Cancer

Interventions

  • GemcitabineDrug

    Standard of care chemotherapy by intravenous infusion

  • CisplatinDrug

    Standard of care chemotherapy by intravenous infusion

  • DurvalumabDrug

    Standard of care immunotherapy by intravenous infusion

  • Trastuzumab deruxtecanDrug

    Experimental therapy by intravenous infusion

  • RilvegostomigDrug

    Experimental therapy by intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Run In: To evaluate the safety and tolerability of T-DXd with rilvegostomigTime frame: Until all patients have completed at least 1 full Cycle (each cycle is 21 days)
  2. Randomized Portion: To evaluate the efficacy of T-DXd with rilvegostomig vs Standard of Care (SoC) in terms of Overall Survival in the FAS (HER2 IHC 3+) populationTime frame: From date of treatment randomization until the date of death from any cause (estimated to be assessed up to 50 months after first subject randomized)

Locations

272 sites in 27 countries. Site status is shown where the registry gives one.

  • Research Site

    Scottsdale, Arizona · Recruiting

  • Research Site

    Tucson, Arizona · Withdrawn

  • Research Site

    Tucson, Arizona · Recruiting

  • Research Site

    Fullerton, California · Recruiting

  • Research Site

    La Jolla, California · Recruiting

  • Research Site

    Los Alamitos, California · Suspended

  • Research Site

    Los Angeles, California · Recruiting

  • Research Site

    Los Angeles, California · Recruiting

  • Research Site

    San Francisco, California · Recruiting

  • Research Site

    Walnut Creek, California · Withdrawn

  • Research Site

    Washington D.C., District of Columbia · Not yet recruiting

  • Research Site

    Washington D.C., District of Columbia · Not yet recruiting

  • Research Site

    Fort Myers, Florida · Recruiting

  • Research Site

    Jacksonville, Florida · Recruiting

  • Research Site

    St. Petersburg, Florida · Recruiting

  • Research Site

    Tampa, Florida · Suspended

  • Research Site

    West Palm Beach, Florida · Recruiting

  • Research Site

    Atlanta, Georgia · Recruiting

  • Research Site

    Coeur d'Alene, Idaho · Withdrawn

  • Research Site

    Chicago, Illinois · Recruiting

  • Research Site

    Niles, Illinois · Recruiting

  • Research Site

    Towson, Maryland · Recruiting

  • Research Site

    Boston, Massachusetts · Withdrawn

  • Research Site

    Worcester, Massachusetts · Withdrawn

  • Research Site

    Detroit, Michigan · Withdrawn

  • Research Site

    Grand Rapids, Michigan · Recruiting

  • Research Site

    Rochester, Minnesota · Recruiting

  • Research Site

    Kansas City, Missouri · Recruiting

  • Research Site

    Kansas City, Missouri · Recruiting

  • Research Site

    St Louis, Missouri · Recruiting

  • Research Site

    Albuquerque, New Mexico · Withdrawn

  • Research Site

    New York, New York · Withdrawn

  • Research Site

    White Plains, New York · Recruiting

  • Research Site

    Cleveland, Ohio · Suspended

  • Research Site

    Cleveland, Ohio · Recruiting

  • Research Site

    Cleveland, Ohio · Recruiting

  • Research Site

    Columbus, Ohio · Recruiting

  • Research Site

    Pittsburgh, Pennsylvania · Not yet recruiting

  • Research Site

    Greenville, South Carolina · Recruiting

  • Research Site

    Nashville, Tennessee · Withdrawn

Showing 40 of 272 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.